This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Clinical Development Remove Cosmetics Remove Drug Delivery Remove Research
article thumbnail

Onychomycosis Therapy Market Set to Balloon Up as Emerging Novel Therapies Continue to Adorn the Space

Delveinsight

SEPTEMBER 20, 2021

Although it was initially believed to be that majority of the Onychomycosis cases are caused by dermatophytes; however, new research revealed that the infections are also caused by non-dermatophyte molds (NDMs) and are more prevalent in warmer climates than previously assumed. Besides, ME1111 (Meiji Seika Pharma Co.,

Marketing 74
Marketing Cosmetics Drug Delivery Clinical Development 74
article thumbnail

Crescita Announces Licensing Agreement for Pliaglis; in China

The Pharma Data

NOVEMBER 4, 2020

(TSX: CTX) (OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research & development (“R&D”) and manufacturing capabilities, today announced that it has entered into an exclusive agreement with Juyou-Biotechnology Co.

Licensing 40
Licensing Licensing Dermatology Production 40
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 32,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024